8-K
filed April 3, 2025, 7:59 PM ET
CIK 0001708331
regulatory
confidence high
sentiment negative
materiality 0.90
Virpax Pharmaceuticals, Inc.: Nasdaq/NYSE listing notice — Nasdaq delisting Virpax; directors and CFO resign effective immediately
Virpax Pharmaceuticals, Inc.
- Nasdaq Hearings Panel determined to delist Virpax due to failure to meet minimum stockholders' equity under Rule 5550(b)(1).
- Trading suspended at open on April 4, 2025; Company not appealing.
- Three directors (Esha Randhawa, Charn Deol, Judy Su) resigned April 2, 2025.
- CFO Usama Chaudhry resigned same day, effective immediately; no disagreements cited.
Key facts
Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.95
Virpax Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
- Exchange
- nasdaq
- Notice
- delisting notice
- Deficiency
- stockholders equity
- Rules
- 5550(b)(1)
Exact text from the filing
April 2, 2025, Virpax Pharmaceuticals, Inc. (the “Company”) received a letter from the Nasdaq Hearings Panel (the “Panel”) indicating that the Panel has determined to delist the Company’s securities from The Nasdaq Stock Market LLC (“Nasdaq”) as a result of the Company’s failure to regain compliance with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”). Trading in the Company’s common stock on Nasdaq will be suspended effective at the open of business on Friday, April 4, 2025. Nasdaq will complete the delisting by filing a Form 25 Notificati
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Judy Su resigned as member of the Board of Directors at Virpax Pharmaceuticals, Inc..
- Action
- resigned
- Role
- member of the Board of Directors
Exact text from the filing
On April 2, 2025, Esha Randhawa, Charn Deol, and Judy Su each resigned from their positions as members of the Board of Directors of the Company, effective immediately.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Charn Deol resigned as member of the Board of Directors at Virpax Pharmaceuticals, Inc..
- Action
- resigned
- Role
- member of the Board of Directors
Exact text from the filing
On April 2, 2025, Esha Randhawa, Charn Deol, and Judy Su each resigned from their positions as members of the Board of Directors of the Company, effective immediately.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Usama Chaudhry resigned as Chief Financial Officer at Virpax Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Chief Financial Officer
Exact text from the filing
On the same date, Usama Chaudhry resigned from his position as Chief Financial Officer of the Company, effective immediately.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Esha Randhawa resigned as member of the Board of Directors at Virpax Pharmaceuticals, Inc..
- Action
- resigned
- Role
- member of the Board of Directors
Exact text from the filing
On April 2, 2025, Esha Randhawa, Charn Deol, and Judy Su each resigned from their positions as members of the Board of Directors of the Company, effective immediately.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.